112 related articles for article (PubMed ID: 29345442)
1. Lung uptake of fluorine-18 fluoroethyl-choline PET-CT in patients with prostate cancer.
Pizzuto DA; Annunziata S; Ieria FP; Caldarella C; Isgrò MA; Lanni V; Bencivenga G; Rufini V; Giordano A
Q J Nucl Med Mol Imaging; 2019 Dec; 63(4):387-393. PubMed ID: 29345442
[TBL] [Abstract][Full Text] [Related]
2. Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?
Castellucci P; Fuccio C; Rubello D; Schiavina R; Santi I; Nanni C; Allegri V; Montini GC; Ambrosini V; Boschi S; Martorana G; Marzola MC; Fanti S
Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):55-63. PubMed ID: 20848281
[TBL] [Abstract][Full Text] [Related]
3. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
[TBL] [Abstract][Full Text] [Related]
4. Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5 ng/ml.
Evangelista L; Cuppari L; Guttilla A; Gardi M; Agostini A; Ruggera L; Basso U; Saladini G
Nucl Med Commun; 2018 Mar; 39(3):260-267. PubMed ID: 29381584
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
[TBL] [Abstract][Full Text] [Related]
6. Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution.
Marzola MC; Chondrogiannis S; Ferretti A; Grassetto G; Rampin L; Massaro A; Castellucci P; Picchio M; Al-Nahhas A; Colletti PM; Marcolongo A; Rubello D
Clin Nucl Med; 2013 Jan; 38(1):e26-32. PubMed ID: 23242060
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic performance of
Samper Ots P; Luis Cardo A; Vallejo Ocaña C; Cabeza Rodríguez MA; Glaria Enríquez LA; Couselo Paniagua ML; Olivera Vegas J
Clin Transl Oncol; 2019 Jun; 21(6):766-773. PubMed ID: 30448957
[TBL] [Abstract][Full Text] [Related]
8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
9. (11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy.
Ceci F; Castellucci P; Mamede M; Schiavina R; Rubello D; Fuccio C; Ambrosini V; Boschi S; Martorana G; Fanti S
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(2):149-55. PubMed ID: 23151910
[TBL] [Abstract][Full Text] [Related]
10. Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/CT in restaging prostate cancer patients: a meta-analysis.
Treglia G; Ceriani L; Sadeghi R; Giovacchini G; Giovanella L
Clin Chem Lab Med; 2014 May; 52(5):725-33. PubMed ID: 24310773
[TBL] [Abstract][Full Text] [Related]
11. PET/CT with (18)F-choline after radical prostatectomy in patients with PSA ≤2 ng/ml. Can PSA velocity and PSA doubling time help in patient selection?
Chiaravalloti A; Di Biagio D; Tavolozza M; Calabria F; Schillaci O
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1418-24. PubMed ID: 26791373
[TBL] [Abstract][Full Text] [Related]
12. PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy.
Giovacchini G; Picchio M; Scattoni V; Garcia Parra R; Briganti A; Gianolli L; Montorsi F; Messa C
Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1106-16. PubMed ID: 20306038
[TBL] [Abstract][Full Text] [Related]
13. Role of
Jiménez Londoño GA; García Vicente AM; Amo-Salas M; Fúnez Mayorga F; López Guerrero MA; Talavera Rubio MP; Gutierrez Martin P; González García B; de la Torre Pérez JA; Soriano Castrejón ÁM
Rev Esp Med Nucl Imagen Mol; 2017; 36(4):241-246. PubMed ID: 28330596
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist
Wieser G; Popp I; Christian Rischke H; Drendel V; Grosu AL; Bartholomä M; Weber WA; Mansi R; Wetterauer U; Schultze-Seemann W; Meyer PT; Jilg CA
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1463-1472. PubMed ID: 28417160
[TBL] [Abstract][Full Text] [Related]
15. Relationship between PSA kinetics and Tc-99m HYNIC PSMA SPECT/CT detection rates of biochemical recurrence in patients with prostate cancer after radical prostatectomy.
Liu C; Zhu Y; Su H; Xu X; Zhang Y; Ye D; Hu S
Prostate; 2018 Dec; 78(16):1215-1221. PubMed ID: 30027591
[TBL] [Abstract][Full Text] [Related]
16. Gleason score at diagnosis predicts the rate of detection of 18F-choline PET/CT performed when biochemical evidence indicates recurrence of prostate cancer: experience with 1,000 patients.
Cimitan M; Evangelista L; Hodolič M; Mariani G; Baseric T; Bodanza V; Saladini G; Volterrani D; Cervino AR; Gregianin M; Puccini G; Guidoccio F; Fettich J; Borsatti E
J Nucl Med; 2015 Feb; 56(2):209-15. PubMed ID: 25552670
[TBL] [Abstract][Full Text] [Related]
17. Spectrum of metastatic and nonmetastatic skeletal findings with dual-phase 18F-FECH PET/CT in patients with biochemical relapse of prostate cancer.
Haroon A; Syed R; Endozo R; Allie R; Freeman A; Emberton M; Bomanji J
Nucl Med Commun; 2017 May; 38(5):407-414. PubMed ID: 28379896
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy.
Giovacchini G; Picchio M; Parra RG; Briganti A; Gianolli L; Montorsi F; Messa C
Clin Nucl Med; 2012 Apr; 37(4):325-31. PubMed ID: 22391699
[TBL] [Abstract][Full Text] [Related]
19. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
[TBL] [Abstract][Full Text] [Related]
20. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?
Castellucci P; Ceci F; Graziani T; Schiavina R; Brunocilla E; Mazzarotto R; Pettinato C; Celli M; Lodi F; Fanti S
J Nucl Med; 2014 Sep; 55(9):1424-9. PubMed ID: 24935990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
